Resmetirom as a Selective Thyroid Hormone Receptor-Beta Agonist in the Management of NAFLD/NASH and MASLD/MASH: A Narrative Literature Review

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent a growing global health burden associated with fibrosis progression, cirrhosis, hepatocellular carcinoma, and increased cardiovascular risk. Despite the increasing prevalence of MASLD/MASH, effective pharmacological treatment options have historically been limited. Resmetirom, a selective thyroid hormone receptor-beta (THR-beta) agonist, has recently emerged as a novel liver-directed therapy targeting key metabolic mechanisms involved in disease progression. This narrative literature review aimed to evaluate the mechanism of action, clinical efficacy, safety profile, and therapeutic potential of resmetirom in the management of MASLD/MASH. A structured literature search was conducted using PubMed, ScienceDirect, and SpringerLink to identify relevant studies published between 2015 and 2025. Eligible publications included randomized controlled trials, extension studies, systematic reviews, meta-analyses, clinical practice guidance documents, and regulatory reports evaluating the efficacy and safety of resmetirom.
Current evidence indicates that resmetirom selectively activates hepatic THR-beta, promoting fatty acid β-oxidation, enhancing mitochondrial function, reducing hepatic triglyceride accumulation, and improving cholesterol metabolism. Phase II and phase III clinical trials, including the pivotal MAESTRO-NASH trial, demonstrated significant reductions in liver fat content, improvements in liver enzymes and atherogenic lipid parameters, and favorable histological outcomes, including MASH resolution and fibrosis improvement. Resmetirom also consistently reduced low-density lipoprotein cholesterol, triglycerides, and apolipoprotein B, suggesting potential cardiometabolic benefits beyond improvements in liver histology. The most commonly reported adverse events were mild-to-moderate gastrointestinal symptoms. In conclusion, resmetirom represents a significant therapeutic advancement in MASLD/MASH and the first liver-directed pharmacological therapy approved for selected patients with non-cirrhotic MASH and moderate-to-advanced fibrosis. Although long-term outcome data remain limited, current evidence supports its role as a promising metabolic-based treatment for improving both hepatic and cardiometabolic outcomes.

Resmetirom; THR-beta agonist; MASLD; MASH

1. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease. Metabolism. 2016;65(8):1038–1048. Available from: https://doi.org/10.1016/j.metabol.2015.12.012 [Google Scholar] [Crossref]

2. Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(Suppl 1):S47–S64. Available from: https://doi.org/10.1016/j.jhep.2014.12.012 [Google Scholar] [Crossref]

3. Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, Kim WR. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81(1):312–320. Available from: https://doi.org/10.1097/HEP.0000000000001112 [Google Scholar] [Crossref]

4. European Medicines Agency. Rezdiffra: European Public Assessment Report. Amsterdam: European Medicines Agency; 2025. Available from: https://www.ema.europa.eu [Google Scholar] [Crossref]

5. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. Available from: https://doi.org/10.1038/s41591-018-0104-9 [Google Scholar] [Crossref]

6. Friedman SL, Pinzani M. Hepatic fibrosis 2022: Unmet needs and a blueprint for the future. Hepatology. 2022;75(2):473–488. Available from: https://doi.org/10.1002/hep.32285 [Google Scholar] [Crossref]

7. Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012–2024. Available from: https://doi.org/10.1016/S0140-6736(19)32517-6 [Google Scholar] [Crossref]

8. Harrison SA, Bashir M, Moussa SE, McCarty K, Frias JP, Taub R, Alkhouri N. Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol Commun. 2021;5(4):573–588. Available from: https://doi.org/10.1002/hep4.1657 [Google Scholar] [Crossref]

9. Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, Alkhouri N, Bashir MR. Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29:2919–2928. Available from: https://doi.org/10.1038/s41591-023-02603-1 [Google Scholar] [Crossref]

10. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497–509. Available from: https://doi.org/10.1056/NEJMoa2309000 [Google Scholar] [Crossref]

11. Loomba R, Mohseni R, Lucas KJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024. [Update final volume, issue, page numbers, and DOI according to the final published version.] [Google Scholar] [Crossref]

12. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in NASH. N Engl J Med. 2021;384(12):1113–1124. Available from: https://doi.org/10.1056/NEJMoa2028395 [Google Scholar] [Crossref]

13. Patel RH, Parikh C, Upadhyay H, Sonaiya S, Ramnath P, Singh S, Patel U, Kothari T. Resmetirom in the management of metabolic dysfunction-associated steatohepatitis (MASH): A comprehensive review of current evidence and therapeutic potential. Cureus. 2024;16(11):e74772. Available from: https://doi.org/10.7759/cureus.74772 [Google Scholar] [Crossref]

14. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen AA. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–861. Available from: https://doi.org/10.1016/S2468-1253(22)00165-0 [Google Scholar] [Crossref]

15. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–1556. Available from: https://doi.org/10.1016/j.jhep.2023.06.003 [Google Scholar] [Crossref]

16. Suvarna R, Shetty S, Pappachan JM. Efficacy and safety of resmetirom, a selective thyroid hormone receptor-beta agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis. Sci Rep. 2024;14:19790. Available from: https://doi.org/10.1038/s41598-024-70242-8 [Google Scholar] [Crossref]

17. Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease. Nat Rev Gastroenterol Hepatol. 2021;18(9):656–670. Available from: https://doi.org/10.1038/s41575-021-00457-0 [Google Scholar] [Crossref]

18. U.S. Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. Silver Spring (MD): U.S. Food and Drug Administration; 2024. Available from: https://www.fda.gov [Google Scholar] [Crossref]

19. Udaikumar J, Nimmagadda R, Lella VV, Achuta KM, Kuppili S, Avula SR, Sarwar R. The comparative safety and efficacy of resmetirom and semaglutide in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review. Pharmacoepidemiology. 2025;4(3):14. Available from: https://doi.org/10.3390/pharma4030014 [Google Scholar] [Crossref]

20. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. Available from: https://doi.org/10.1002/hep.28431 [Google Scholar] [Crossref]

• Migrant Health in Morocco: Between Law and Reality
• CaknaMinda: An Educator-Centred Mobile App for Early Screening of Mental Health and Schizophrenia Risks
• Health System and Nursing Strategies for Enhancing Male Participation in Family Planning: Evidence from Tema General Hospital, Ghana.
• From Īśvara-Praṇidhāna to Parā-Bhakti: Convergent Paths of Aṣṭāṅga Yoga and Bhakti Yoga
• Evidence-Based Psycho-Oncological Interventions: A Multimodal Approach to Supportive Care